CN112206223A - 透皮释放活性物质的系统 - Google Patents
透皮释放活性物质的系统 Download PDFInfo
- Publication number
- CN112206223A CN112206223A CN202011091427.9A CN202011091427A CN112206223A CN 112206223 A CN112206223 A CN 112206223A CN 202011091427 A CN202011091427 A CN 202011091427A CN 112206223 A CN112206223 A CN 112206223A
- Authority
- CN
- China
- Prior art keywords
- carrier material
- active substance
- backing layer
- tts
- hook
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000013543 active substance Substances 0.000 title claims abstract description 135
- 230000037317 transdermal delivery Effects 0.000 title description 6
- 239000012876 carrier material Substances 0.000 claims abstract description 107
- 238000000034 method Methods 0.000 claims abstract description 20
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 8
- 239000007788 liquid Substances 0.000 claims description 31
- 125000002091 cationic group Chemical group 0.000 claims description 16
- 239000000463 material Substances 0.000 claims description 12
- -1 polyethylene Polymers 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- 239000000853 adhesive Substances 0.000 claims description 11
- 230000001070 adhesive effect Effects 0.000 claims description 7
- 230000004888 barrier function Effects 0.000 claims description 5
- 239000004952 Polyamide Substances 0.000 claims description 4
- 229920002647 polyamide Polymers 0.000 claims description 4
- 229920000728 polyester Polymers 0.000 claims description 4
- 229920000642 polymer Polymers 0.000 claims description 4
- 239000004698 Polyethylene Substances 0.000 claims description 3
- 239000004743 Polypropylene Substances 0.000 claims description 3
- 229920000573 polyethylene Polymers 0.000 claims description 3
- 229920001155 polypropylene Polymers 0.000 claims description 3
- 229920002635 polyurethane Polymers 0.000 claims description 3
- 239000004814 polyurethane Substances 0.000 claims description 3
- 238000010276 construction Methods 0.000 claims 1
- 239000002985 plastic film Substances 0.000 claims 1
- 229920006255 plastic film Polymers 0.000 claims 1
- 230000000717 retained effect Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 12
- 229940079593 drug Drugs 0.000 abstract description 9
- 239000010410 layer Substances 0.000 description 60
- 229920006395 saturated elastomer Polymers 0.000 description 15
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 239000010408 film Substances 0.000 description 9
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 150000002500 ions Chemical class 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 239000004753 textile Substances 0.000 description 8
- 239000004820 Pressure-sensitive adhesive Substances 0.000 description 7
- 239000004599 antimicrobial Substances 0.000 description 7
- 239000004744 fabric Substances 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 6
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 229960002428 fentanyl Drugs 0.000 description 5
- IVLVTNPOHDFFCJ-UHFFFAOYSA-N fentanyl citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 IVLVTNPOHDFFCJ-UHFFFAOYSA-N 0.000 description 5
- 229960004194 lidocaine Drugs 0.000 description 5
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 5
- 229920006280 packaging film Polymers 0.000 description 5
- 239000012785 packaging film Substances 0.000 description 5
- 150000001298 alcohols Chemical class 0.000 description 4
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 239000000017 hydrogel Substances 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 238000004806 packaging method and process Methods 0.000 description 4
- 230000002441 reversible effect Effects 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- XSVMFMHYUFZWBK-NSHDSACASA-N Rivastigmine Chemical compound CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 XSVMFMHYUFZWBK-NSHDSACASA-N 0.000 description 3
- 239000000730 antalgic agent Substances 0.000 description 3
- 239000002111 antiemetic agent Substances 0.000 description 3
- 229940125683 antiemetic agent Drugs 0.000 description 3
- 239000003125 aqueous solvent Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 239000003623 enhancer Substances 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 229960003980 galantamine Drugs 0.000 description 3
- ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 description 3
- MFWNKCLOYSRHCJ-BTTYYORXSA-N granisetron Chemical compound C1=CC=C2C(C(=O)N[C@H]3C[C@H]4CCC[C@@H](C3)N4C)=NN(C)C2=C1 MFWNKCLOYSRHCJ-BTTYYORXSA-N 0.000 description 3
- 229960003727 granisetron Drugs 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 230000035515 penetration Effects 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 229920003023 plastic Polymers 0.000 description 3
- 229960004136 rivastigmine Drugs 0.000 description 3
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 2
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 2
- 229930182837 (R)-adrenaline Natural products 0.000 description 2
- ARIWANIATODDMH-AWEZNQCLSA-N 1-lauroyl-sn-glycerol Chemical compound CCCCCCCCCCCC(=O)OC[C@@H](O)CO ARIWANIATODDMH-AWEZNQCLSA-N 0.000 description 2
- BHIZVZJETFVJMJ-UHFFFAOYSA-N 2-hydroxypropyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCC(C)O BHIZVZJETFVJMJ-UHFFFAOYSA-N 0.000 description 2
- OSDLLIBGSJNGJE-UHFFFAOYSA-N 4-chloro-3,5-dimethylphenol Chemical compound CC1=CC(O)=CC(C)=C1Cl OSDLLIBGSJNGJE-UHFFFAOYSA-N 0.000 description 2
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- ARIWANIATODDMH-UHFFFAOYSA-N Lauric acid monoglyceride Natural products CCCCCCCCCCCC(=O)OCC(O)CO ARIWANIATODDMH-UHFFFAOYSA-N 0.000 description 2
- OCJYIGYOJCODJL-UHFFFAOYSA-N Meclizine Chemical compound CC1=CC=CC(CN2CCN(CC2)C(C=2C=CC=CC=2)C=2C=CC(Cl)=CC=2)=C1 OCJYIGYOJCODJL-UHFFFAOYSA-N 0.000 description 2
- DMULVCHRPCFFGV-UHFFFAOYSA-N N,N-dimethyltryptamine Chemical compound C1=CC=C2C(CCN(C)C)=CNC2=C1 DMULVCHRPCFFGV-UHFFFAOYSA-N 0.000 description 2
- 229940127450 Opioid Agonists Drugs 0.000 description 2
- 101800000989 Oxytocin Proteins 0.000 description 2
- 102400000050 Oxytocin Human genes 0.000 description 2
- XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 description 2
- LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 description 2
- 239000004098 Tetracycline Substances 0.000 description 2
- 240000008042 Zea mays Species 0.000 description 2
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 2
- 239000003522 acrylic cement Substances 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 229940035676 analgesics Drugs 0.000 description 2
- 230000003474 anti-emetic effect Effects 0.000 description 2
- 239000012736 aqueous medium Substances 0.000 description 2
- 229960000686 benzalkonium chloride Drugs 0.000 description 2
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 2
- 239000003114 blood coagulation factor Substances 0.000 description 2
- 239000003576 central nervous system agent Substances 0.000 description 2
- 229960003260 chlorhexidine Drugs 0.000 description 2
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 2
- 238000002716 delivery method Methods 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- XYYVYLMBEZUESM-UHFFFAOYSA-N dihydrocodeine Natural products C1C(N(CCC234)C)C2C=CC(=O)C3OC2=C4C1=CC=C2OC XYYVYLMBEZUESM-UHFFFAOYSA-N 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 description 2
- 229960003638 dopamine Drugs 0.000 description 2
- 230000005684 electric field Effects 0.000 description 2
- 229960005139 epinephrine Drugs 0.000 description 2
- 239000000122 growth hormone Substances 0.000 description 2
- LLPOLZWFYMWNKH-CMKMFDCUSA-N hydrocodone Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)CC(=O)[C@@H]1OC1=C2C3=CC=C1OC LLPOLZWFYMWNKH-CMKMFDCUSA-N 0.000 description 2
- 229960000240 hydrocodone Drugs 0.000 description 2
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 2
- 125000001841 imino group Chemical group [H]N=* 0.000 description 2
- 150000002475 indoles Chemical class 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 238000009940 knitting Methods 0.000 description 2
- 229960001474 meclozine Drugs 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 229960004503 metoclopramide Drugs 0.000 description 2
- TTWJBBZEZQICBI-UHFFFAOYSA-N metoclopramide Chemical compound CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC TTWJBBZEZQICBI-UHFFFAOYSA-N 0.000 description 2
- 229960005181 morphine Drugs 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 description 2
- 229960001723 oxytocin Drugs 0.000 description 2
- 239000003961 penetration enhancing agent Substances 0.000 description 2
- 239000000813 peptide hormone Substances 0.000 description 2
- 229920000058 polyacrylate Polymers 0.000 description 2
- 238000003825 pressing Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 2
- 229940026235 propylene glycol monolaurate Drugs 0.000 description 2
- LOUPRKONTZGTKE-LHHVKLHASA-N quinidine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@H]2[C@@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-LHHVKLHASA-N 0.000 description 2
- 229940044551 receptor antagonist Drugs 0.000 description 2
- 239000002464 receptor antagonist Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000011877 solvent mixture Substances 0.000 description 2
- 229960002180 tetracycline Drugs 0.000 description 2
- 229930101283 tetracycline Natural products 0.000 description 2
- 235000019364 tetracycline Nutrition 0.000 description 2
- 150000003522 tetracyclines Chemical class 0.000 description 2
- ICUTUKXCWQYESQ-UHFFFAOYSA-N triclocarban Chemical compound C1=CC(Cl)=CC=C1NC(=O)NC1=CC=C(Cl)C(Cl)=C1 ICUTUKXCWQYESQ-UHFFFAOYSA-N 0.000 description 2
- QCHFTSOMWOSFHM-WPRPVWTQSA-N (+)-Pilocarpine Chemical compound C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C QCHFTSOMWOSFHM-WPRPVWTQSA-N 0.000 description 1
- DBGIVFWFUFKIQN-UHFFFAOYSA-N (+-)-Fenfluramine Chemical compound CCNC(C)CC1=CC=CC(C(F)(F)F)=C1 DBGIVFWFUFKIQN-UHFFFAOYSA-N 0.000 description 1
- XWTYSIMOBUGWOL-UHFFFAOYSA-N (+-)-Terbutaline Chemical compound CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1 XWTYSIMOBUGWOL-UHFFFAOYSA-N 0.000 description 1
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- FELGMEQIXOGIFQ-CYBMUJFWSA-N (3r)-9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1h-carbazol-4-one Chemical compound CC1=NC=CN1C[C@@H]1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-CYBMUJFWSA-N 0.000 description 1
- TVYLLZQTGLZFBW-ZBFHGGJFSA-N (R,R)-tramadol Chemical compound COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 description 1
- VAZJLPXFVQHDFB-UHFFFAOYSA-N 1-(diaminomethylidene)-2-hexylguanidine Polymers CCCCCCN=C(N)N=C(N)N VAZJLPXFVQHDFB-UHFFFAOYSA-N 0.000 description 1
- PWWDCRQZITYKDV-UHFFFAOYSA-N 1-benzyl-2-piperazin-1-ylbenzimidazole Chemical compound C1CNCCN1C1=NC2=CC=CC=C2N1CC1=CC=CC=C1 PWWDCRQZITYKDV-UHFFFAOYSA-N 0.000 description 1
- LEBVLXFERQHONN-UHFFFAOYSA-N 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide Chemical compound CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-UHFFFAOYSA-N 0.000 description 1
- NZJXADCEESMBPW-UHFFFAOYSA-N 1-methylsulfinyldecane Chemical compound CCCCCCCCCCS(C)=O NZJXADCEESMBPW-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical class N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 1
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 1
- 229940099451 3-iodo-2-propynylbutylcarbamate Drugs 0.000 description 1
- WYVVKGNFXHOCQV-UHFFFAOYSA-N 3-iodoprop-2-yn-1-yl butylcarbamate Chemical compound CCCCNC(=O)OCC#CI WYVVKGNFXHOCQV-UHFFFAOYSA-N 0.000 description 1
- IJVCSMSMFSCRME-UHFFFAOYSA-N 3-methyl-2,4,4a,5,6,7,7a,13-octahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7,9-diol Chemical compound C12CCC(O)C3OC4=C5C32CCN(C)C1CC5=CC=C4O IJVCSMSMFSCRME-UHFFFAOYSA-N 0.000 description 1
- 102000035037 5-HT3 receptors Human genes 0.000 description 1
- 108091005477 5-HT3 receptors Proteins 0.000 description 1
- USSIQXCVUWKGNF-UHFFFAOYSA-N 6-(dimethylamino)-4,4-diphenylheptan-3-one Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 USSIQXCVUWKGNF-UHFFFAOYSA-N 0.000 description 1
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- QTGIAADRBBLJGA-UHFFFAOYSA-N Articaine Chemical compound CCCNC(C)C(=O)NC=1C(C)=CSC=1C(=O)OC QTGIAADRBBLJGA-UHFFFAOYSA-N 0.000 description 1
- 239000005552 B01AC04 - Clopidogrel Substances 0.000 description 1
- 239000005528 B01AC05 - Ticlopidine Substances 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 206010006784 Burning sensation Diseases 0.000 description 1
- ZKLPARSLTMPFCP-UHFFFAOYSA-N Cetirizine Chemical compound C1CN(CCOCC(=O)O)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZKLPARSLTMPFCP-UHFFFAOYSA-N 0.000 description 1
- WJLVQTJZDCGNJN-UHFFFAOYSA-N Chlorhexidine hydrochloride Chemical compound Cl.Cl.C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 WJLVQTJZDCGNJN-UHFFFAOYSA-N 0.000 description 1
- 235000001258 Cinchona calisaya Nutrition 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- PLDUPXSUYLZYBN-UHFFFAOYSA-N Fluphenazine Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 PLDUPXSUYLZYBN-UHFFFAOYSA-N 0.000 description 1
- 102400000921 Gastrin Human genes 0.000 description 1
- 108010052343 Gastrins Proteins 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 description 1
- 102000003834 Histamine H1 Receptors Human genes 0.000 description 1
- 108090000110 Histamine H1 Receptors Proteins 0.000 description 1
- 239000004831 Hot glue Substances 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 1
- PWWVAXIEGOYWEE-UHFFFAOYSA-N Isophenergan Chemical compound C1=CC=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1 PWWVAXIEGOYWEE-UHFFFAOYSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- XADCESSVHJOZHK-UHFFFAOYSA-N Meperidine Chemical compound C=1C=CC=CC=1C1(C(=O)OCC)CCN(C)CC1 XADCESSVHJOZHK-UHFFFAOYSA-N 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- WJAJPNHVVFWKKL-UHFFFAOYSA-N Methoxamine Chemical compound COC1=CC=C(OC)C(C(O)C(C)N)=C1 WJAJPNHVVFWKKL-UHFFFAOYSA-N 0.000 description 1
- UEQUQVLFIPOEMF-UHFFFAOYSA-N Mianserin Chemical compound C1C2=CC=CC=C2N2CCN(C)CC2C2=CC=CC=C21 UEQUQVLFIPOEMF-UHFFFAOYSA-N 0.000 description 1
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 description 1
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 1
- BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920002413 Polyhexanide Polymers 0.000 description 1
- 229920002367 Polyisobutene Polymers 0.000 description 1
- BKRGVLQUQGGVSM-KBXCAEBGSA-N Revanil Chemical compound C1=CC(C=2[C@H](N(C)C[C@H](C=2)NC(=O)N(CC)CC)C2)=C3C2=CNC3=C1 BKRGVLQUQGGVSM-KBXCAEBGSA-N 0.000 description 1
- QCHFTSOMWOSFHM-UHFFFAOYSA-N SJ000285536 Natural products C1OC(=O)C(CC)C1CC1=CN=CN1C QCHFTSOMWOSFHM-UHFFFAOYSA-N 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 206010040893 Skin necrosis Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 239000000150 Sympathomimetic Substances 0.000 description 1
- XEFQLINVKFYRCS-UHFFFAOYSA-N Triclosan Chemical compound OC1=CC(Cl)=CC=C1OC1=CC=C(Cl)C=C1Cl XEFQLINVKFYRCS-UHFFFAOYSA-N 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000016383 Zea mays subsp huehuetenangensis Nutrition 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000012790 adhesive layer Substances 0.000 description 1
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229960000836 amitriptyline Drugs 0.000 description 1
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 229940125709 anorectic agent Drugs 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940127003 anti-diabetic drug Drugs 0.000 description 1
- 230000001090 anti-dopaminergic effect Effects 0.000 description 1
- 239000003416 antiarrhythmic agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 229940127218 antiplatelet drug Drugs 0.000 description 1
- 239000002830 appetite depressant Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000013011 aqueous formulation Substances 0.000 description 1
- 229960003831 articaine Drugs 0.000 description 1
- 229940092732 belladonna alkaloid Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229960001950 benzethonium chloride Drugs 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- 239000012867 bioactive agent Substances 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000003592 biomimetic effect Effects 0.000 description 1
- GERIGMSHTUAXSI-UHFFFAOYSA-N bis(8-methyl-8-azabicyclo[3.2.1]octan-3-yl) 4-phenyl-2,3-dihydro-1h-naphthalene-1,4-dicarboxylate Chemical compound CN1C(C2)CCC1CC2OC(=O)C(C1=CC=CC=C11)CCC1(C(=O)OC1CC2CCC(N2C)C1)C1=CC=CC=C1 GERIGMSHTUAXSI-UHFFFAOYSA-N 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 229940019700 blood coagulation factors Drugs 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229960003150 bupivacaine Drugs 0.000 description 1
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 description 1
- 229960001736 buprenorphine Drugs 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 239000002327 cardiovascular agent Substances 0.000 description 1
- 229940125692 cardiovascular agent Drugs 0.000 description 1
- PHIQHXFUZVPYII-UHFFFAOYSA-N carnitine Chemical compound C[N+](C)(C)CC(O)CC([O-])=O PHIQHXFUZVPYII-UHFFFAOYSA-N 0.000 description 1
- 229960000678 carnitine chloride Drugs 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 229960001803 cetirizine Drugs 0.000 description 1
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 description 1
- 229960001927 cetylpyridinium chloride Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- UKTAZPQNNNJVKR-KJGYPYNMSA-N chembl2368925 Chemical compound C1=CC=C2C(C(O[C@@H]3C[C@@H]4C[C@H]5C[C@@H](N4CC5=O)C3)=O)=CNC2=C1 UKTAZPQNNNJVKR-KJGYPYNMSA-N 0.000 description 1
- AOXOCDRNSPFDPE-UKEONUMOSA-N chembl413654 Chemical compound C([C@H](C(=O)NCC(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@@H](N)CCC(O)=O)C1=CC=C(O)C=C1 AOXOCDRNSPFDPE-UKEONUMOSA-N 0.000 description 1
- 229960002152 chlorhexidine acetate Drugs 0.000 description 1
- 229960004504 chlorhexidine hydrochloride Drugs 0.000 description 1
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 1
- 229960001076 chlorpromazine Drugs 0.000 description 1
- 229940001468 citrate Drugs 0.000 description 1
- 229960002881 clemastine Drugs 0.000 description 1
- YNNUSGIPVFPVBX-NHCUHLMSSA-N clemastine Chemical compound CN1CCC[C@@H]1CCO[C@@](C)(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 YNNUSGIPVFPVBX-NHCUHLMSSA-N 0.000 description 1
- 229960002896 clonidine Drugs 0.000 description 1
- 229960003009 clopidogrel Drugs 0.000 description 1
- GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 description 1
- 229960004126 codeine Drugs 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 239000013039 cover film Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- WDEFBBTXULIOBB-WBVHZDCISA-N dextilidine Chemical compound C=1C=CC=CC=1[C@@]1(C(=O)OCC)CCC=C[C@H]1N(C)C WDEFBBTXULIOBB-WBVHZDCISA-N 0.000 description 1
- 229960002069 diamorphine Drugs 0.000 description 1
- SOROIESOUPGGFO-UHFFFAOYSA-N diazolidinylurea Chemical compound OCNC(=O)N(CO)C1N(CO)C(=O)N(CO)C1=O SOROIESOUPGGFO-UHFFFAOYSA-N 0.000 description 1
- 229960001083 diazolidinylurea Drugs 0.000 description 1
- RBOXVHNMENFORY-DNJOTXNNSA-N dihydrocodeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC RBOXVHNMENFORY-DNJOTXNNSA-N 0.000 description 1
- 229960000920 dihydrocodeine Drugs 0.000 description 1
- 229960004704 dihydroergotamine Drugs 0.000 description 1
- HESHRHUZIWVEAJ-JGRZULCMSA-N dihydroergotamine Chemical compound C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(N21)=O)(C)NC(=O)[C@H]1CN([C@H]2[C@@H](C3=CC=CC4=NC=C([C]34)C2)C1)C)C1=CC=CC=C1 HESHRHUZIWVEAJ-JGRZULCMSA-N 0.000 description 1
- 229960004166 diltiazem Drugs 0.000 description 1
- HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 description 1
- SPCNPOWOBZQWJK-UHFFFAOYSA-N dimethoxy-(2-propan-2-ylsulfanylethylsulfanyl)-sulfanylidene-$l^{5}-phosphane Chemical compound COP(=S)(OC)SCCSC(C)C SPCNPOWOBZQWJK-UHFFFAOYSA-N 0.000 description 1
- 229960004192 diphenoxylate Drugs 0.000 description 1
- HYPPXZBJBPSRLK-UHFFFAOYSA-N diphenoxylate Chemical compound C1CC(C(=O)OCC)(C=2C=CC=CC=2)CCN1CCC(C#N)(C=1C=CC=CC=1)C1=CC=CC=C1 HYPPXZBJBPSRLK-UHFFFAOYSA-N 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
- 229960003413 dolasetron Drugs 0.000 description 1
- 229960001253 domperidone Drugs 0.000 description 1
- FGXWKSZFVQUSTL-UHFFFAOYSA-N domperidone Chemical compound C12=CC=CC=C2NC(=O)N1CCCN(CC1)CCC1N1C2=CC=C(Cl)C=C2NC1=O FGXWKSZFVQUSTL-UHFFFAOYSA-N 0.000 description 1
- 229960003530 donepezil Drugs 0.000 description 1
- 239000003136 dopamine receptor stimulating agent Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 229960002179 ephedrine Drugs 0.000 description 1
- 229960004943 ergotamine Drugs 0.000 description 1
- OFKDAAIKGIBASY-VFGNJEKYSA-N ergotamine Chemical compound C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(N21)=O)(C)NC(=O)[C@H]1CN([C@H]2C(C3=CC=CC4=NC=C([C]34)C2)=C1)C)C1=CC=CC=C1 OFKDAAIKGIBASY-VFGNJEKYSA-N 0.000 description 1
- XCGSFFUVFURLIX-UHFFFAOYSA-N ergotaminine Natural products C1=C(C=2C=CC=C3NC=C(C=23)C2)C2N(C)CC1C(=O)NC(C(N12)=O)(C)OC1(O)C1CCCN1C(=O)C2CC1=CC=CC=C1 XCGSFFUVFURLIX-UHFFFAOYSA-N 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 229960001582 fenfluramine Drugs 0.000 description 1
- 239000011094 fiberboard Substances 0.000 description 1
- 229960002690 fluphenazine Drugs 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 229940001447 lactate Drugs 0.000 description 1
- 238000003475 lamination Methods 0.000 description 1
- 229940070765 laurate Drugs 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229950009727 lerisetron Drugs 0.000 description 1
- 229960003587 lisuride Drugs 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229960001571 loperamide Drugs 0.000 description 1
- RDOIQAHITMMDAJ-UHFFFAOYSA-N loperamide Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(C(=O)N(C)C)CCN(CC1)CCC1(O)C1=CC=C(Cl)C=C1 RDOIQAHITMMDAJ-UHFFFAOYSA-N 0.000 description 1
- 235000009973 maize Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
- 229960003105 metformin Drugs 0.000 description 1
- 229960001797 methadone Drugs 0.000 description 1
- 229960005192 methoxamine Drugs 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 229960003955 mianserin Drugs 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000003149 muscarinic antagonist Substances 0.000 description 1
- 229940035363 muscle relaxants Drugs 0.000 description 1
- 239000003158 myorelaxant agent Substances 0.000 description 1
- 229940105132 myristate Drugs 0.000 description 1
- NETZHAKZCGBWSS-CEDHKZHLSA-N nalbuphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]1(O)CC[C@@H]3O)CN2CC1CCC1 NETZHAKZCGBWSS-CEDHKZHLSA-N 0.000 description 1
- 229960000805 nalbuphine Drugs 0.000 description 1
- UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 description 1
- 229960004127 naloxone Drugs 0.000 description 1
- DQCKKXVULJGBQN-XFWGSAIBSA-N naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 description 1
- 229960003086 naltrexone Drugs 0.000 description 1
- 239000003887 narcotic antagonist Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 229960005343 ondansetron Drugs 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229960002085 oxycodone Drugs 0.000 description 1
- RARSHUDCJQSEFJ-UHFFFAOYSA-N p-Hydroxypropiophenone Chemical compound CCC(=O)C1=CC=C(O)C=C1 RARSHUDCJQSEFJ-UHFFFAOYSA-N 0.000 description 1
- 229960003379 pancuronium bromide Drugs 0.000 description 1
- NPIJXCQZLFKBMV-YTGGZNJNSA-L pancuronium bromide Chemical compound [Br-].[Br-].C[N+]1([C@@H]2[C@@H](OC(C)=O)C[C@@H]3CC[C@H]4[C@@H]5C[C@@H]([C@@H]([C@]5(CC[C@@H]4[C@@]3(C)C2)C)OC(=O)C)[N+]2(C)CCCCC2)CCCCC1 NPIJXCQZLFKBMV-YTGGZNJNSA-L 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- VOKSWYLNZZRQPF-GDIGMMSISA-N pentazocine Chemical compound C1C2=CC=C(O)C=C2[C@@]2(C)[C@@H](C)[C@@H]1N(CC=C(C)C)CC2 VOKSWYLNZZRQPF-GDIGMMSISA-N 0.000 description 1
- 229960005301 pentazocine Drugs 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 229960000482 pethidine Drugs 0.000 description 1
- 239000008252 pharmaceutical gel Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229960001416 pilocarpine Drugs 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 1
- 229920006267 polyester film Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001195 polyisoprene Polymers 0.000 description 1
- 229920006254 polymer film Polymers 0.000 description 1
- 229920000098 polyolefin Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229960003089 pramipexole Drugs 0.000 description 1
- FASDKYOPVNHBLU-ZETCQYMHSA-N pramipexole Chemical compound C1[C@@H](NCCC)CCC2=C1SC(N)=N2 FASDKYOPVNHBLU-ZETCQYMHSA-N 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960003910 promethazine Drugs 0.000 description 1
- 229960003712 propranolol Drugs 0.000 description 1
- MCSINKKTEDDPNK-UHFFFAOYSA-N propyl propionate Chemical compound CCCOC(=O)CC MCSINKKTEDDPNK-UHFFFAOYSA-N 0.000 description 1
- 229960001404 quinidine Drugs 0.000 description 1
- 229960000948 quinine Drugs 0.000 description 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 229960001879 ropinirole Drugs 0.000 description 1
- UHSKFQJFRQCDBE-UHFFFAOYSA-N ropinirole Chemical compound CCCN(CCC)CCC1=CC=CC2=C1CC(=O)N2 UHSKFQJFRQCDBE-UHFFFAOYSA-N 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 229960002052 salbutamol Drugs 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 1
- 229960002646 scopolamine Drugs 0.000 description 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
- 229960002930 sirolimus Drugs 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 231100000245 skin permeability Toxicity 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229940086735 succinate Drugs 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- GGCSSNBKKAUURC-UHFFFAOYSA-N sufentanil Chemical compound C1CN(CCC=2SC=CC=2)CCC1(COC)N(C(=O)CC)C1=CC=CC=C1 GGCSSNBKKAUURC-UHFFFAOYSA-N 0.000 description 1
- 229960004739 sufentanil Drugs 0.000 description 1
- KQKPFRSPSRPDEB-UHFFFAOYSA-N sumatriptan Chemical compound CNS(=O)(=O)CC1=CC=C2NC=C(CCN(C)C)C2=C1 KQKPFRSPSRPDEB-UHFFFAOYSA-N 0.000 description 1
- 229960003708 sumatriptan Drugs 0.000 description 1
- 229940127230 sympathomimetic drug Drugs 0.000 description 1
- 229960001685 tacrine Drugs 0.000 description 1
- YLJREFDVOIBQDA-UHFFFAOYSA-N tacrine Chemical compound C1=CC=C2C(N)=C(CCCC3)C3=NC2=C1 YLJREFDVOIBQDA-UHFFFAOYSA-N 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 229960000195 terbutaline Drugs 0.000 description 1
- TUNFSRHWOTWDNC-UHFFFAOYSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 229960005001 ticlopidine Drugs 0.000 description 1
- PHWBOXQYWZNQIN-UHFFFAOYSA-N ticlopidine Chemical compound ClC1=CC=CC=C1CN1CC(C=CS2)=C2CC1 PHWBOXQYWZNQIN-UHFFFAOYSA-N 0.000 description 1
- 229960001402 tilidine Drugs 0.000 description 1
- 229960002312 tolazoline Drugs 0.000 description 1
- JIVZKJJQOZQXQB-UHFFFAOYSA-N tolazoline Chemical compound C=1C=CC=CC=1CC1=NCCN1 JIVZKJJQOZQXQB-UHFFFAOYSA-N 0.000 description 1
- 229960004380 tramadol Drugs 0.000 description 1
- TVYLLZQTGLZFBW-GOEBONIOSA-N tramadol Natural products COC1=CC=CC([C@@]2(O)[C@@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-GOEBONIOSA-N 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- LLPOLZWFYMWNKH-UHFFFAOYSA-N trans-dihydrocodeinone Natural products C1C(N(CCC234)C)C2CCC(=O)C3OC2=C4C1=CC=C2OC LLPOLZWFYMWNKH-UHFFFAOYSA-N 0.000 description 1
- 238000013271 transdermal drug delivery Methods 0.000 description 1
- 229960001325 triclocarban Drugs 0.000 description 1
- 229960003500 triclosan Drugs 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 229960001722 verapamil Drugs 0.000 description 1
- 238000009941 weaving Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/02—Details
- A61N1/04—Electrodes
- A61N1/0404—Electrodes for external use
- A61N1/0408—Use-related aspects
- A61N1/0428—Specially adapted for iontophoresis, e.g. AC, DC or including drug reservoirs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/02—Adhesive bandages or dressings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2271—Neuropeptide Y
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH], i.e. somatotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/02—Details
- A61N1/04—Electrodes
- A61N1/0404—Electrodes for external use
- A61N1/0408—Use-related aspects
- A61N1/0428—Specially adapted for iontophoresis, e.g. AC, DC or including drug reservoirs
- A61N1/0432—Anode and cathode
- A61N1/0436—Material of the electrode
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/02—Details
- A61N1/04—Electrodes
- A61N1/0404—Electrodes for external use
- A61N1/0408—Use-related aspects
- A61N1/0428—Specially adapted for iontophoresis, e.g. AC, DC or including drug reservoirs
- A61N1/0448—Drug reservoir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/20—Applying electric currents by contact electrodes continuous direct currents
- A61N1/30—Apparatus for iontophoresis, i.e. transfer of media in ionic state by an electromotoric force into the body, or cataphoresis
- A61N1/303—Constructional details
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M2037/0007—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin having means for enhancing the permeation of substances through the epidermis, e.g. using suction or depression, electric or magnetic fields, sound waves or chemical agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2207/00—Methods of manufacture, assembly or production
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Radiology & Medical Imaging (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Anesthesiology (AREA)
- Medical Informatics (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
本发明涉及一种用于释放药物活性物质的透皮治疗系统(TTS),其包括背衬层(7)和至少一种含活性物质的载体材料(1),其中,至少一个固定元件(6a‑6d)位于含活性物质的载体材料和背衬层之间,通过该固定元件将含活性物质的载体材料固定在背衬层上。本发明还涉及一种用于在钩和环带节段存在的情况下将含活性物质的载体材料固定到TTS的背衬层上的方法,并涉及钩和环带在将药物或治疗活性物质透皮或离子电渗给药至患者的方法中的用途。
Description
本申请是母案为中国发明专利申请201480070086.3的分案申请。
本发明涉及用于递送治疗有效量的药物活性物质至生物体的新系统。
本发明优选涉及一种易于操作的系统,所述系统用于透皮递送溶解在液体中的治疗有效量的药物活性物质,更优选用于通过离子电渗疗法透皮递送阳离子活性物质。
肠胃外给药的透皮途径与其它给药途径相比提供了许多优点。通过皮肤施用药物的方法和系统在药学领域是众所周知的。透皮给药通常利用被动透皮系统(例如,透皮治疗系统,TTS),它经由皮肤通过扩散将确定量的药物活性物质供给生物体。
具体地说,溶解在液体中的活性物质的透皮传输存在以下问题:含有活性物质的凝胶或海绵布或无纺织的载体材料必须保持与背衬层分开,在TTS中的活性物质连同背衬层被固定至皮肤,其原因在于如果不采用这种方式则不能保证长时间的储存稳定性,或其原因在于活性物质可能必须保持冷却,或其原因在于活性物质可能对氧化敏感。然后贴含药剂的使用者必须通过除去封闭薄膜将含活性物质的载体材料从它的通常密封并因此不透液性包装移出,并将含活性物质的载体材料转移至透皮治疗系统(TTS)的背衬层,并将含活性物质的载体材料固定在背衬层上。但是,一直因为病菌转移的风险,理想的是使用者应不用他或她的手指触摸含活性物质的载体材料,和也应理想地不使用任何辅助的手段以实现转移。
因此,通常的操作是将TTS背衬层面朝下放置在含活性物质的载体材料的向上打开的包装上,然后将载体材料按在TTS背衬层上。当此后再次将TTS从打开的包装中取出时,含活性物质的载体材料被保持附着于TTS背衬层,所述含活性物质的载体材料与TTS背衬层结合以形成在实际意义上的TTS,但是这并不总是可靠地发生。经常或至少偶尔,含活性物质的载体材料仅仅被留在包装中。
发生此问题的一个情况是采用离子电渗疗法的方法的情况,当被动透皮药物递送是对于某些类型的药物非常低效时采用离子电渗疗法。特别是离子化的药物往往无法以治疗有效量被动通过皮肤。
离子电渗疗法的方法最初是由勒杜克在1908年和甚至更早地在 US 222276(1879)和US 486902(1892)中描述的。从那以后,离子电渗疗法在商业上被用于离子带电治疗活性分子,如毛果芸香碱,利多卡因,地塞米松,利多卡因和芬太尼的透皮递送。
离子电渗疗法一般是基于以下的基本原理的递送方法:电流的应用使得可用的外部能量通过改善活性成分的离子通过皮肤而增加药物渗透通过皮肤的膜能力。
当带有正电荷(例如,阳离子活性物质)的离子置于离子电渗系统的阳极中或离子电渗系统的阳极下方时,电流的应用将导致被施加至这些离子的脉冲,所述脉冲在向阴极的电场的方向上移动这些离子并使其远离阳极,所述阴极被放置在皮肤的附近。在此过程中,阳离子药物通过皮肤的输送被改善或促进。
可以用各种形式的活性药物成分、最优选用具有电荷并且由此在电场中发展到越过障碍(例如,皮肤)的能力的形式进行离子电渗。
典型的离子电渗药物递送系统包含电解电系统,所述电解电系统包括阳极和阴极,并且被放置在患者的不同皮肤区域-优选邻近的皮肤区域-,每个电极被通过导线连接到外部电源。在一般情况下,这是一个微处理器控制的电仪器。这种类型的装置是已知的,包括非常简单的设计(例如,US 5685837或US 6745071)或其他更复杂的系统,其中本领域的技术人员具有所述系统的原理知识。利多卡因和芬太尼的透皮离子电渗系统已经在美国被成功推出。通过离子电渗疗法递送药物的系统的非常特别详细的描述在WO 2012/071175中被找到。
US 5558633涉及离子电渗疗法的装置,其特别适用于从液体或从凝胶化水性制剂递送药物。然而,在这种装置中,药物活性物质的离子电渗疗法给药可以被“背景”电解质的存在破坏(例如参见 Luzardo-Alvarez,A.,等人,Proceedings of the InternationalSymposium on Controlled Release of bioactive Materials(2000),第 27版,第159至160页)。此外,关于离子电渗疗法的装置的设计,还需求本身并不具有作为“背景”抗衡离子的破坏性影响的医药凝胶或液体。
尽管仍然存在各种不足之处,离子电渗疗法已经被证明在所有这些情况(其中常规的TTS不足以确保这种活性物质的治疗有效剂量的快速给药)下是有用的递送方法。然而,存在采用离子电渗疗法的固有风险,即副作用如皮肤刺激,皮肤发红,灼热或其他皮肤坏死可以特别在增加电流强度中或在长时间实施离子电渗治疗中发生。另一方面,在电流强度的增加对于更高剂量治疗活性物质的施用可以是完全理想的,因为运输的离子数目与的每单位时间的电流的水平成正比。
因此鉴于上述,本发明解决的问题是提供一种方法,通过所述方法,含有活性物质的载体材料可以从它的包可靠地去除和固定到用于随后应用的目的的TTS背衬层–无论是否有或没有通过离子电渗疗法的增强–若无此则需要含活性物质的载体材料被手触摸或需要额外的辅助以实现转移。
这个问题是由初始分类的TTS解决,所述TTS包括背衬层和至少一种含活性物质的载体材料,其中所述含活性物质的载体材料和背衬层之间的至少一个保持元件固定含活性物质的载体至背衬层。
在本发明的优选实施方案中,保持元件被配置为钩和环带的伸长地成型的段。
在本申请钩和环带的提及是可以被理解为意指纺织品,任意地经常可释放的(可放松的)紧固装置,其基础是牙钻的原理。通常情况下,仿生工具包括以下:纤维的两个纺织带,一个显示软性具倒刺毛的钩或蘑菇头,另一个相反地成环。如果将它们压在一起则它们结合形成高速紧固件,所述紧固件具有或多或少的抵抗力,但以任何速率是可逆的。纺织钩和环带由聚酰胺,聚酯或聚烯烃纤维组成。所述钩在织造过程中或以后被引入钩带中。钩和环带和接触紧固件也可以通过用压敏粘合剂涂敷而在反面被赋予自粘性。
在本发明中,设置在TTS的背衬层上的钩和环带形成钩侧,而含活性物质的载体材料承担环侧的功能。通过将安装在TTS的背衬层上的保持元件按在包装(含有包含活性物质的载体材料并且向上通过预先去除封闭膜被打开)的上侧,本发明使钩和环带通过钩与载体材料接合,当TTS从包装拆下时附着至TTS的保持元件,而当包装随后再次被除去时不被留在包装中。
在一般情况下,含活性物质的载体材料位于包装中,其中恰在将载体材料加上活性物质转移至TTS的背衬层前通过除去封闭薄膜,打开所述包装。
含活性物质的载体材料是液态饱和的,并且如此附着到包装膜。为了从包装膜释放载体材料,因此需要力(X1)。现在,如果在没有额外辅助如,例如,手指或用于转移的夹持元件的情况下,将载体材料转移到TTS,则TTS平放到载体材料上和被按下。这会导致液体饱和载体材料附加地附着至按下的TTS(聚合物膜/聚酯膜)。然而,附着至TTS的附着力(=Ftts)类似于附着至包装的附着力(=F包装)。在TTS已被按下后,在再次除去TTS时,两个附着力的大小决定了含活性物质的载体材料是否保持附着至TTS或备选地附着至包。除非附着至TTS的附着力(Ftts)比附着至包装膜的附着力(F包装)显著更大,存在以下风险:液体饱和载体材料仍然保留在包装中,而不是象所希望的附着至TTS。
为了从包装膜中连续转移含活性物质的载体材料至TTS,附着力必须被改变,使得它们显著不同:
Ftts>>F包装
含活性物质的载体材料附着至包装薄膜的附着力几乎不能降低。即使抗粘涂层减少这种附着力,但也不显著,其原因在于液体的粘度。表面的轮廓也不引起在附着力的任何变化,其原因在于液体填充表面轮廓和置换空气夹杂(air inclusion)。
因此,增加对TTS的附着力(Ftts)将是稳定地确保传输过程中的问题的解决方案。
本发明采用钩和环带,以增加附着TTS的附着力(Ftts)。由于钩和环带,含活性物质的载体材料(Ftts)的附着力显著增加。这是因为,钩和环带甚至可以在潮湿状态下发挥功能。由于含活性物质的载体材料被按在钩和环带上,载体材料的纤维通过钩与钩和环带的钩接合。所以钩和环带即使在潮湿的环境中也显著增大附着力(Ftts),保证了液体饱和载体材料从包装转移到TTS的背衬层。
背衬层是指用于本申请目的的基本上自支撑的片材体,其覆盖皮肤的部分,在所述皮肤的部分中药物活性物质被透皮递送至生物体。如果所述TTS不是通过压敏粘合剂覆盖膏剂(overplaster)附着至皮肤上,则所述背衬层还便利地具有将系统固定到皮肤上的功能,这是通过背衬层面对皮肤的那一侧的均匀或定型地压敏粘合剂工具来实现的,其中用于含活性物质的载体材料的区域至少不含压敏粘合剂。
在本发明的进一步的实施方案,背衬层是闭合背衬层。闭合背衬层特别是用于液体和水蒸汽、防止液体或水蒸汽通过背衬层逸出到外部的阻挡层,所述逸出在药物活性待递送是液体或溶解在液体的情况下将导致系统脱水。本发明中的闭合背衬层可以包括塑料(如聚乙烯或聚丙烯或聚酯或聚氨酯或聚酰胺)的自支撑膜,其基本特性是,它构成了水、水蒸汽或水混合的有机溶剂的充分可靠的阻断物。提到的塑料的合适的自支撑膜的厚度范围为5至300μm,优选10至200μm,更优选从12至150μm。
闭合背衬层可另外还包含或结合到用于加强的非闭合载体层。所述非闭合载体层可以适当地是机织纺织品(梭织纺织品)(woven textile)纤维或非织造(无纺织的)纤维网或毡材料或一些其它纤维素材料。非闭合性载体层和闭合背衬层之间的结合可以通过在压力下的层压或通过挤出或通过用合适的粘合剂粘结来建立。合适的粘合剂可以包括聚异戊二烯或聚异丁烯或聚丙烯酸酯或其他的聚硅氧烷共聚物。
自粘层也可以被提供到封闭顶层下侧,即,面朝皮肤侧。上述的粘合剂优选丙烯酸系粘接剂适用作自粘材料。
在进一步的实施方案中,含活性物质的载体材料是水凝胶,或采用液体饱和的载体材料,或被撒上粉状活性物质。本发明中的液体可以理解为活性物在溶剂(优选含水溶剂)中的溶液,否则,可以替代地理解为活性物质在合适的分散介质或乳化介质中的分散体或乳液。通过载体材料,使用非织造(无纺织的)纤维网型材料或机织纺织品 (梭织纺织品)材料或不通过采用独立地移动的针的纬编产生的针织物或海绵状材料,采用形成凝胶的聚合物,或否则任选采用形成凝胶的聚合物。
在本发明的一个优选实施方案中,伸长地成型的钩和环带的形状与含活性物质的载体材料的形状相匹配。当含活性物质的载体材料具有矩形形状时,所述伸长地成型的钩和环带的长度优选对应于矩形形状的含活性物质的载体材料的多个侧面中的一个的长度。当含活性物质的载体材料具有圆形或椭圆形时,所述伸长地成型的钩和环带的形状优选是弓形的圆形段的形状,所述弓形的圆形段具有对应于圆形或椭圆形的含活性物质的载体材料的半径的半径。
适用于本发明目的的钩和环带是自粘的,即它们将其自粘反面附着到背衬层。但也有可能采用合适的粘合剂,例如丙烯酸类粘合剂或双组分粘合剂或热熔粘合剂以将钩和环带紧固至背衬层。
所述伸长地成型的钩和环带的宽度可以在宽的范围内变化。钩和环带不必覆盖整个区域(TTS中的含活性物质的载体材料在所述区域上延伸),不管含活性物质的载体材料几何形状如何,相反的是,如果所述伸长地成型的钩和环带仅覆盖的区的部分或仅覆盖的区的一个部分,这就足够了。另外,在这种情况下,钩和环带也可以仅位于邻近区域的侧缘中,或钩和环带也可以被配置成宽度范围为2至15毫米,优选3至10毫米的圆周带(带材)。
本发明还可以包括两个或多个钩和环带,所述钩和环带被放置例如,在区域的相对两侧,在所述区域中含活性物质的载体材料被固定到TTS或将被固定到TTS。
本发明还提供在钩和环带段的存在下将含活性物质的载体材料附着于TTS背衬层的方法。这涉及到使在通过预先除去封闭膜而向上打开的包装中的含活性物质的载体材料接近闭合背衬层和设置在其上的钩和环带段。然后,将包装与存在于其中的含活性物质的载体材料一起按在闭合背衬层上的钩和环带段上。此后,可以将包装释放并除去,留下含活性物质的载体材料固定在钩和环带段以及闭合背衬层。
本发明还提供了一种使用钩和环带作为透皮治疗系统(TTS)的组成部分或作为离子电渗透皮治疗系统的组成部分的方法。
本发明进一步包含在用于将阳离子活性物质透皮或离子电渗给药至需要采用这种活性物质治疗的病人的方法中使用钩和环带的方法。
本发明的系统是特别适用于特别与具有阳离子结构的治疗活性物质,特别是在其分子中具有的氨基或亚氨基的活性物质相结合。
因此本发明适于透皮给药,特别是通过离子电渗疗法给药止痛剂如芬太尼或吗啡,止吐剂如格拉司琼或其他中枢神经系统药物如卡巴拉汀或加兰他敏。
当本发明的系统被用于这样的活性物质的透皮给药时,液体饱和载体材料用作基质或储器(储库),阳离子活性物质从基质或储器(储库)中被递送到皮肤,然后被动地或在离子电渗协助下通过皮肤。
具有阳离子结构的活性物质通常是如下活性物质:是在带正电荷的离子(阳离子)的形式中的活性物质,或能够在水性介质中形成带正电的离子的活性物质。例如许多生物活性剂具有在水性介质中容易解离成带正电荷的离子和抗衡离子的官能团,其实例是碱性活性物质的可溶性盐。
术语“活性物质”具体包含治疗活性剂,药理活性剂或当给予人或动物时具有有利的效果的其它试剂。
术语“活性物质”一般指药物活性物质或药物,即,治疗性活性物质。表达“活性物质”也进一步包含兽药中使用的试剂。
本发明特别适用于透皮给药,特别是通过离子电渗疗法给药活性物质,所述活性物质例如
-阿片样激动剂,包括镇痛剂,如芬太尼,舒芬太尼,吗啡,吗啡衍生物如可待因或如海洛因,二氢可待因,氢化吗啡,羟考酮,氢可酮(二氢可待因酮),哌替啶,洛哌丁胺,地芬诺酯,美沙酮,曲马多或替利定;
-阿片样拮抗剂如纳洛酮,纳曲酮;
-混合阿片激动剂/拮抗剂,如丁丙诺啡,喷他佐辛,纳布啡;
-止吐剂包括5-HT3受体拮抗剂,例如格拉司琼,来立司琼,昂丹司琼,多拉司琼,甲氧氯普胺和也包括抗多巴胺能药物如多潘立酮,并且还包括H1受体拮抗剂,诸如,例如,异丙嗪或氯苯甲嗪(美克洛嗪)和也包括毒蕈碱拮抗剂,例如东莨菪碱;
-作用于中枢神经系统的药物化合物,如利斯的明,加兰他敏,他克林,多奈哌齐,并且还例如普拉克索,肾上腺素,多巴胺,罗匹尼罗,尼古丁,氟奋乃静,氯丙嗪,苯并二氮类,单胺再摄取抑制剂如阿米替林,抗抑郁剂如米安色林;
-生物碱,如麦角胺,双氢麦角胺,美西麦角或利舒脲,颠茄生物碱;
-肽,特别是肽类激素,如胰岛素和催产素或凝血因子和生长激素;
-阳离子活性吲哚化合物,例如N-二甲基色胺,舒马曲坦或赛洛新;
-局部麻醉剂如利多卡因,buprivacaine,阿替卡因,普鲁卡因;
-胃肠道活性治疗剂,如肉碱氯化物(康胃素)或甲氧氯普胺;
-肌肉松弛剂,如泮库溴铵(vancuronium bromide);
-抗生素如四环素,基于四环素的制剂,卡那霉素,基于卡那霉素的制剂,庆大霉素,基于庆大霉素的制剂或奎宁;
-减食欲剂如芬氟拉明或麻黄碱;
-抗糖尿病药物诸如二甲双胍;
-血小板聚集抑制剂,例如,噻氯匹定或氯吡格雷;
-抗心律失常药,如奎尼丁或利多卡因;
-心脏或心血管药物如多巴胺,去甲肾上腺素,甲氧明,肾上腺素,维拉帕米,地尔硫卓,普萘洛尔,可乐定,妥拉唑啉;
-拟交感神经剂例如沙丁胺醇或特布他林;
-抗组胺药,如氯马斯汀,西替利嗪或氯苯沙明。
在一个优选实施方案中,活性物质来自以下组成的组:阳离子吲哚化合物,特别是选自以下组成的组:阳离子吲哚化合物,N-二甲基- 色胺和赛洛新,前述组也包括这些阳离子活性吲哚化合物的药学上适宜的盐。
上述阳离子活性物质也可以存在于药学上合适的盐的形式。药学上合适的盐的实例包括盐酸盐,氢溴酸,氢碘酸,硫酸盐,磷酸盐,乳酸盐,柠檬酸盐,酒石酸盐,水杨酸盐,琥珀酸盐,马来酸盐,葡糖酸盐,甲磺酸盐,月桂酸盐,十二烷酸盐,肉豆蔻酸酯,棕榈酸盐和硬脂酸盐,但不限于这些。
离子电渗疗法期间的电流的强度应理想地不超过600μA/cm2的值,从而避免烧皮肤或皮肤上的烧灼感。起动电压一般是在0.5至10 伏的范围,这取决于两个电极和皮肤在两者之间的区域之间的电阻,其可以通常为50kΩ或更大。
在进一步的实施方案中,液体饱和载体材料含有阳离子活性物质或其盐,所述阳离子活性物质或其盐的含量为0.1至20wt%,优选0.2 至10wt%,更优选为2至10wt%,,最优选3至5wt%,基于载体材料中液体的总重量。
在本发明的液体饱和载体材料的液体优选为水或含水溶剂混合物。溶剂混合物中水的比例优选为至少15wt%,更优选至少40wt%,基于液体的总重量。
在本发明的进一步的实施方案中,溶剂混合物的水含量或比例是在80至99wt%的范围内。
术语“含水溶剂混合物”通常包含液体混合物,其中含有水和至少一种另外的溶剂,所述另外的溶剂是极性水混溶的有机溶剂,例如,醇如乙醇,异丙醇或甘油。
本发明还包含以下应用:其中将阳离子活性物质与至少一种另外的活性物质相组合使用,所述是另外的活性物质选自包括具有中性电荷的活性剂的组,并甚至可能还包括阴离子活性物质。
本发明的系统通常采用能够通过被动扩散通过皮肤或适于皮肤离子电渗渗透的活性物质。
在进一步的实施方案中,液体饱和的载体材料可以是水凝胶组合物,在这种情况下,额外地存在形成凝胶的聚合物,其可从由聚丙烯酸酯或盐和纤维素衍生物,如羟基丙基甲基纤维素,羟丙基纤维素或羟基乙基纤维素的组中选择。
在离子电渗疗法中使用水凝胶制剂是特别有利的,因为,在这种情况下,离子强度可以通过改变水凝胶中的水的比例进行调整。因此,容易的是,调节离子强度以在任何特定的情况下优化离子电渗过程的效力。
在进一步的实施方案中,在液体饱和载体材料中的液体的pH在以下范围内:3至8,优选5.5至7,更优选为约6。
通常优选的是,建立当TTS施加到皮肤时与皮肤pH无显著差异的pH。在进一步的实施方案中,皮肤pH值的变化±4.0或更小,约±3.5 或更小,约±3.0或更小,约±2.5或更小,约±2.0或更小,约±1.5或更小,约±1.0或更小,或约±0.5或更小。用于调节或建立pH的物质和缓冲剂是本领域的技术人员已知的。
液体饱和载体材料可以任选含有其它的添加剂,在这种情况下,添加剂可选自增溶剂,皮肤渗透增强剂,防腐剂和抗微生物剂。
在此背景下,作为一般含义,术语“溶解度改进剂”应被理解为在能够有助于提高阳离子活性剂在液体中的溶解度的化合物。这是可以通过以下实现:调节存在于液体中的阳离子活性物质和其它成分之间可能的相互作用,或者额外掺入合适的辅助材料。
可替代地,通过改变晶形实现活性物质的溶解度。
增溶剂的实例包括水,二醇,如丙二醇和甘油,一元醇如乙醇,丙醇和高级醇,二甲基亚砜(DMSO),二甲基甲酰胺,N,N-二甲基乙酰胺,N-取代烷基氮杂环烷基-2-酮。
术语“皮肤渗透增强剂”进一步包含,其中增加活性物质、特别是阳离子活性物质的皮肤的渗透性的具体化合物。由于这种皮肤透过性的增强,活性物质通过皮肤而进入血液循环的速率增加。
渗透增强剂的实例包括二甲基亚砜(DMSO),N,N-二甲基乙酰胺(DMA),癸基甲基亚砜(C 10MSO),聚乙二醇单月桂酸酯 (PEGML),丙二醇(PG),丙二醇单月桂酸酯(PGML),甘油单月桂酸酯(GML),卵磷脂,1-取代的烷基氮杂环烷基-2-酮,特别是碘代癸基(indodecylcyl)氮杂环庚烷-2-酮,醇等。
渗透增强剂也可以选自植物油,例如,红花油,棉籽油或玉蜀黍 (玉米)油。
含两个或多个不同渗透增强剂的组合是同样可用的。
作为一般含义,术语“抗微生物剂”是进一步应被理解为适合于防止微生物在药物制剂中、特别是在本发明的液体饱和载体材料的液体中的生长的试剂。
合适的抗微生物剂的实例包括氯己定的盐,例如碘代丙炔丁基氨基甲酸酯,尿素醛(diazolidinylurea),氯己定二葡糖酸盐,氯己定醋酸盐,氯己定异硫化羟酸盐或氯己定盐酸盐。其它阳离子抗微生物剂也同样可以使用,例如苯扎氯铵,苄索氯铵,三氯卡班(三氯二苯脲)(triclocarbon),聚六亚甲基双胍,氯化鲸蜡基吡啶鎓,氯化甲苄乙氧铵(methylbenzethonium chloride)。
其他抗微生物剂包括卤代酚类化合物,如2,4,4'-三氯-2-羟基二苯醚(三氯生),对氯间二甲苯酚(parachlorometa xylenol)(PCMX),对羟基苯甲酸甲酯和短链醇,如乙醇,丙醇等。抗微生物剂的总浓度优选在0.01至2wt%的范围内,基于其中存在抗微生物剂的液体的总重量。
适宜的载体材料可以是纤维板层(plies),纺织物(机织物),不是用独立地移动的针产生的纬编针织物的针织物,海绵,海绵布,针织缝合的非织造(无纺织的)纤维网或毡织(felted-woven)造织物或毡样材料等。
本发明进一步提供了使用上述系统作为离子电渗贴剂的整体组成部分、优选作为贴剂的阳极储器(储库)的方法。
实例
现在将通过举例的方式参考附图说明本发明及其效果,其中
图1以示意形式表示来自下面的,即来自皮肤侧的发明的TTS;
图2以示意性的形式示出来自上面的、即从皮肤远程端的发明的 TTS;
图3a,3b,3c和3d以示意形式示出,在成分步骤中,含活性物质的载体材料如何从其分开储存的包装中取出并固定至TTS的背衬层。
图1表示,1为含活性物质的载体材料,其具有圆形形状并且已经被放入在TTS的左手区域的位置,而具有在右手侧的开口3的覆盖膜2给出了电极4的视图,线上电器5和四个弧形(弓形)钩和环带 6a,6b,6c和6d。然后将含有活性物质的载体材料(未示出)进一步在接下来的步骤中,压在钩和环带6a,6b,6c和6d上,并使其与钩和环带6a,6b,6c和6d牢牢固定。
图2基本上示出背衬层7,电流供给5和5'通过所述背衬层7并且分别在左侧和右侧是可见的。可以在描绘的中心发现具有电池和电子控制的电流供给单元8。
图3a在顶部示出背衬层7,在背衬层7上设置有两个钩和环带段 6a和6c,并在底部示出含活性物质的载体材料1,所述含活性物质的载体材料1处于向上打开的包装10中,由被预先剥离的封闭膜打开所述包装10(未描述)。
图3b示出含活性物质的载体材料1如何在仍然在打开的包装10 中的同时接近背衬层7以及钩和环带段6a和6c。
图3c显示了含活性物质的载体材料1如何与包装10一起从下面在箭头方向上被按在钩和环带段6a和6c上以及背衬层7上。
图3d示出如何向下去除包装10,而保持含活性物质的载体材料1 固定至所述钩和环带段6a和6c,并且由此保持含活性物质的载体材料1固定至背衬层7。
1.一种用于药物活性物质的递送的透皮治疗系统(TTS),其包含背衬层和至少一种含活性物质的载体材料,其中所述含活性物质的载体材料和背衬层之间的至少一个保持元件固定含活性物质的载体材料至背衬层。
2.如实施方式1所述的TTS,其特征在于所述保持元件是钩和环带的伸长地成型的段的钩侧。
3,如实施方式1或2所述的TTS,其特征在于所述的TTS经由压敏粘合剂覆盖膏剂或经由背衬层面朝皮肤的那一侧的均匀地或定型地压敏粘合剂工具附着至皮肤,其中用于含活性物质的载体材料的区域至少不含压敏粘合剂。
4.如实施方式1至3中一项或多项所述的TTS,其特征在于背衬层是闭合背衬层,其是用于液体和水蒸汽的阻挡层。
5.如实施方式4所述的TTS,其特征在于闭合背衬层包括塑料如聚乙烯或聚丙烯或聚酯或聚氨酯或聚酰胺的自支撑膜,并具有范围是 5至300μm,优选10至200μm,更优选12至150μm的厚度。
6.如实施方式1至5中一项或多项所述的TTS,其特征在于所述伸长地成型的钩和环带的形状与含活性物质的载体材料的形状相匹配。
7.如实施方式1至6中的一项或多项所述的TTS,其特征在于所述含活性物质的载体材料具有圆形或椭圆形形状,并且所述伸长地成型的钩和环带具有弓形的圆形段的形状,所述弓形的圆形段具有对应于圆形或椭圆形的液体饱和载体材料的半径的半径。
8.如实施方式1至7中的一项或多项所述的TTS,其特征在于所述伸长地成型的钩和环带的宽度可以改变,其中,所述钩和环带不覆盖所述背衬层的整个区域,在TTS中的含活性物质的载体材料在所述背衬层上延伸。
9.如实施方式8所述的TTS,其特征在于所述伸长地成型的钩和环带仅覆盖区域的部分或部分的一部分,优选被放置在区域的侧边缘附近的区,在TTS中的含活性物质的载体材料在所述区域上延伸。
10.如实施方式1至9中的一项或多项所述的TTS,其特征在于,它包括放置在区域的相反两侧的两个或多个钩和环带,在TTS中的含活性物质的载体材料在区域上延伸。
11.如实施方式1至10中的一项或多项所述的TTS,其特征在于所述含活性物质的载体材料是液体饱和的载体材料,其中所述载体材料是非织造(无纺织的)纤维网,纺织品材料,机织纺织品(梭织纺织品),不通过采用独立地移动的针头的纬编产生的针织物,海绵状的材料,海绵布或形成凝胶的聚合物。
12.在钩和环带段的存在下将含活性物质的载体材料附着于TTS 背衬层的方法,所述方法包括使在通过预先除去封闭膜而向上打开的包装中的含活性物质的载体材料接近背衬层和设置在其上的钩和环带段,然后,将包装与存在于其中的含活性物质的载体材料一起按在背衬层上的钩和环带段上,此后将包装释放并除去,留下含活性物质的载体材料固定至钩和环带段以及背衬层。
13.一种在用于将治疗活性活性物质透皮或离子电渗给药至需要采用这种活性物质治疗的病人的方法中、使用钩和环带以将含活性物质的载体材料附着到闭合背衬层的方法。
14.如实施方式13所述的方法,其特征在于具有阳离子结构的治疗活性物质是具有在其分子中的氨基或亚氨基的活性物质。
15.如实施方式13或14所述的方法,其用于透皮离子电渗给药镇痛剂,如芬太尼或吗啡,止吐剂如格拉司琼或其他中枢神经系统药物如卡巴拉汀或加兰他敏或肽,特别是肽类激素,如胰岛素和催产素或凝血因子和生长激素。
16.如实施方式13至15中任一项所述的方法,其特征在于所述含活性物质的载体材料是液体饱和载体材料,其用作基质或储库,由此将治疗活性物质从所述基质或储库递送至皮肤,然后治疗活性物质被动地或经由离子电渗增强通过皮肤。
Claims (10)
1.一种用于药物活性物质的释放的透皮治疗系统(TTS),其包含背衬层(7)和至少一种含活性物质的载体材料(1),其中所述含活性物质的载体材料和背衬层之间具有至少一个固定元件,其用于将含活性物质的载体材料固定到背衬层上,其特征在于,治疗活性物质具有阳离子结构并且所述载体材料是液体浸渍的,所述固定元件是钩和环带的伸长成型的节段的钩侧,所述伸长成型的钩和环带的形状与含活性物质的载体材料的形状相匹配。
2.根据权利要求1所述的TTS,其特征在于,所述TTS在皮肤上的固定是通过粘帖性配置的覆盖贴剂进行的,或者通过背衬层(7)面朝皮肤的一侧的平面粘贴或图案形粘贴的构造,其中一种或多种含活性物质的载体材料的一个或多个区域至少是无粘贴剂的。
3.根据权利要求1或2所述的TTS,其特征在于,所述背衬层(7)是闭合背衬层,其是液体和水蒸汽的阻挡层。
4.根据权利要求3所述的TTS,其特征在于,所述闭合背衬层(7)由塑料薄膜如聚乙烯或聚丙烯或聚酯或聚氨酯或聚酰胺构成,并具有范围是5至300μm,优选10至200μm,更优选12至150μm的厚度。
5.根据权利要求1至4中的一项或多项所述的TTS,其特征在于所述含活性物质的载体材料具有圆形或椭圆形形状,并且所述伸长成型的钩和环带具有弓形环段的形状,所述弓形环段具有相应于圆形或椭圆形的液体浸渍的载体材料的半径的半径。
6.根据权利要求1至5中的一项或多项所述的TTS,其特征在于所述伸长成型的钩和环带的宽度可以改变,其中,所述钩和环带不覆盖所述背衬层的整个区域,在TTS中的含活性物质的载体材料在所述区域上伸展。
7.根据权利要求6所述的TTS,其特征在于,所述伸长成型的钩和环带仅覆盖所述区域的一部分,优选被放置在所述区域靠近侧边缘的区,在TTS中所述含活性物质的载体材料在所述区域上伸展。
8.根据权利要求1至7中的一项或多项所述的TTS,其特征在于,包含设置在所述区域的对侧的多个钩和环带,在TTS中所述含活性物质的载体材料在所述区域上伸展。
9.根据权利要求1至8中的一项或多项所述的TTS,其特征在于所述含活性物质的载体材料是液体浸渍的载体材料(1),其中所述载体材料是无纺布、纺织材料、织物、针织物或者海绵状的材料、海绵布或形成凝胶的聚合物。
10.在钩和环带节段的存在下将含活性物质的载体材料(1)固定于TTS背衬层的方法,其中将向上地通过预先剥离封闭膜而打开包装中的含活性物质的载体材料接近背衬层和设置在其上的钩和环带节段,然后,将包装与存在于其中的含活性物质的载体材料通过压力一起按在背衬层上的钩和环带节段上,此后将包装解开并除去,含活性物质的载体材料固定地留存在钩和环带节段以及背衬层上。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP13199189.5A EP2886153A1 (de) | 2013-12-20 | 2013-12-20 | System für die transdermale Abgabe von Wirkstoff |
EP13199189.5 | 2013-12-20 | ||
CN201480070086.3A CN105873634A (zh) | 2013-12-20 | 2014-12-17 | 透皮释放活性物质的系统 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201480070086.3A Division CN105873634A (zh) | 2013-12-20 | 2014-12-17 | 透皮释放活性物质的系统 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN112206223A true CN112206223A (zh) | 2021-01-12 |
Family
ID=49880573
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201480070086.3A Pending CN105873634A (zh) | 2013-12-20 | 2014-12-17 | 透皮释放活性物质的系统 |
CN202011091427.9A Pending CN112206223A (zh) | 2013-12-20 | 2014-12-17 | 透皮释放活性物质的系统 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201480070086.3A Pending CN105873634A (zh) | 2013-12-20 | 2014-12-17 | 透皮释放活性物质的系统 |
Country Status (13)
Country | Link |
---|---|
US (2) | US10485967B2 (zh) |
EP (2) | EP2886153A1 (zh) |
JP (1) | JP6560679B2 (zh) |
KR (1) | KR20160102002A (zh) |
CN (2) | CN105873634A (zh) |
AU (1) | AU2014365899B2 (zh) |
BR (1) | BR112016013278B1 (zh) |
CA (1) | CA2934318C (zh) |
ES (1) | ES2661836T3 (zh) |
HK (1) | HK1223583A1 (zh) |
MX (1) | MX2016008138A (zh) |
RU (1) | RU2687090C1 (zh) |
WO (1) | WO2015090583A1 (zh) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108159563A (zh) * | 2016-12-07 | 2018-06-15 | 恩客斯(上海)商贸有限公司 | 电皮肤裹布 |
EP3698843B1 (en) * | 2017-04-10 | 2022-02-23 | Battelle Memorial Institute | Mixed ionic electronic conductors for improved charge transport in electrotherapeutic devices |
CN107670022B (zh) * | 2017-09-06 | 2020-07-10 | 华中农业大学 | 一种催产素透皮剂及其制备方法和应用 |
CN111278503B (zh) * | 2017-09-12 | 2023-12-05 | Lts勒曼治疗系统股份公司 | 离子电渗微针装置 |
DE102017123809A1 (de) * | 2017-10-12 | 2019-04-18 | Swiss Spa System Ltd. | In einer Hand haltbares Gerät zur elektrisch unterstützten Hautbehandlung, Zusatzteil für dieses Gerät und Blister für dieses Zusatzteil |
WO2020143633A1 (zh) * | 2019-01-08 | 2020-07-16 | 上海肤泰科技有限公司 | 一种用于透皮离子电渗给药的皮肤贴膜 |
US11364225B2 (en) * | 2019-08-21 | 2022-06-21 | Bn Intellectual Properties, Inc. | Pharmaceutical formulation for treating symptoms of migraine and cluster headaches, and method of using the same |
CN110694036A (zh) * | 2019-08-21 | 2020-01-17 | 云南中医药大学 | 一种具有缓释功能的三伏贴及其制备方法 |
EP4135712A4 (en) * | 2020-04-16 | 2024-04-17 | Pike Therapeutics Inc | TRANSDERMAL MICRODOSING OF PSYCHEDELIC DERIVATIVES |
KR20230012501A (ko) | 2020-05-19 | 2023-01-26 | 사이빈 아이알엘 리미티드 | 중수소화된 트립타민 유도체 및 사용 방법 |
US11312684B1 (en) | 2021-02-10 | 2022-04-26 | Eleusis Therapeutics Us, Inc. | Pharmaceutically acceptable salts of psilocin and uses thereof |
KR20240006525A (ko) * | 2021-03-31 | 2024-01-15 | 라이프 씨에이치엔지 엘엘씨 | 환각제의 치료적 투여를 위한 경피 시스템, 제제 및 방법 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5645526A (en) * | 1994-09-30 | 1997-07-08 | Becton Dickinson And Company | Apparatus and method for ensuring compatibility of a reusable iontophoretic controller with an iontophoretic patch |
US20020019652A1 (en) * | 1999-07-08 | 2002-02-14 | Cyclotec Advanced Medical Technologies | Two part tens bandage |
US20040101551A1 (en) * | 2000-08-30 | 2004-05-27 | Thorsten Selzer | Transdermal therapeutic system for releasing venlafaxine |
CN1708291A (zh) * | 2001-12-05 | 2005-12-14 | Lts勒曼治疗系统股份公司 | 具有改良的长期附着舒适性的透皮治疗体系 |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US486902A (en) | 1892-11-29 | Galvanic body-battery | ||
US222276A (en) | 1879-12-02 | Improvement in combined galvanic and medicated pad | ||
JPS5514343Y2 (zh) * | 1975-11-22 | 1980-04-01 | ||
JPS5270787A (en) | 1975-12-10 | 1977-06-13 | Nippon Telegr & Teleph Corp <Ntt> | Mechanical operation unit |
AU657681B2 (en) | 1990-03-30 | 1995-03-23 | Alza Corporation | Device and method for iontophoretic drug delivery |
DE4014913C2 (de) | 1990-05-10 | 1996-05-15 | Lohmann Therapie Syst Lts | Miniaturisiertes transdermales therapeutisches System für die Iontophorese |
JP2542792B2 (ja) * | 1992-11-05 | 1996-10-09 | ベクトン・ディッキンソン・アンド・カンパニー | ユ―ザ作動型のイオン導入式装置 |
CN1191800C (zh) * | 1996-07-02 | 2005-03-09 | 美国3M公司 | 医用粘性复合物和包装袋 |
JP4154016B2 (ja) | 1997-12-30 | 2008-09-24 | 久光製薬株式会社 | イオントフォレーシス装置およびその組み立て方法 |
US7127285B2 (en) * | 1999-03-12 | 2006-10-24 | Transport Pharmaceuticals Inc. | Systems and methods for electrokinetic delivery of a substance |
US6553253B1 (en) * | 1999-03-12 | 2003-04-22 | Biophoretic Therapeutic Systems, Llc | Method and system for electrokinetic delivery of a substance |
US6745071B1 (en) | 2003-02-21 | 2004-06-01 | Birch Point Medical, Inc. | Iontophoretic drug delivery system |
EP1608433B1 (en) * | 2003-03-31 | 2009-03-11 | ALZA Corporation | Electrotransport device having a reservoir housing having a flexible conductive element |
CN101790373A (zh) * | 2007-05-31 | 2010-07-28 | 费廷药业股份有限公司 | 烟草生物碱储库型经皮贴剂 |
CN102202728A (zh) * | 2008-09-05 | 2011-09-28 | 特拉旺蒂药物股份有限公司 | 电离子透入药物传送组装结构 |
AR074047A1 (es) * | 2008-09-09 | 2010-12-22 | Transcu Ltd | Sistemas, dispositivos, y metodos para suministrar energia a dispositivos, por ejemplo dispositivos de administracion transdermica y/o para controlarlos |
US8329210B2 (en) * | 2008-09-23 | 2012-12-11 | Pharmapatch, Llc | Twin transdermal drug delivery patch |
CA2817824A1 (en) | 2010-11-23 | 2012-05-31 | Nupathe, Inc. | User-activated self-contained co-packaged iontophoretic drug delivery system |
JP5755623B2 (ja) | 2012-09-28 | 2015-07-29 | 株式会社 資生堂 | シート電極 |
-
2013
- 2013-12-20 EP EP13199189.5A patent/EP2886153A1/de not_active Withdrawn
-
2014
- 2014-12-17 RU RU2016129497A patent/RU2687090C1/ru not_active IP Right Cessation
- 2014-12-17 EP EP14815239.0A patent/EP3082942B1/de active Active
- 2014-12-17 ES ES14815239.0T patent/ES2661836T3/es active Active
- 2014-12-17 KR KR1020167019531A patent/KR20160102002A/ko not_active Application Discontinuation
- 2014-12-17 JP JP2016541100A patent/JP6560679B2/ja active Active
- 2014-12-17 CN CN201480070086.3A patent/CN105873634A/zh active Pending
- 2014-12-17 WO PCT/EP2014/003399 patent/WO2015090583A1/de active Application Filing
- 2014-12-17 MX MX2016008138A patent/MX2016008138A/es active IP Right Grant
- 2014-12-17 CA CA2934318A patent/CA2934318C/en active Active
- 2014-12-17 CN CN202011091427.9A patent/CN112206223A/zh active Pending
- 2014-12-17 US US15/105,821 patent/US10485967B2/en active Active
- 2014-12-17 BR BR112016013278-5A patent/BR112016013278B1/pt active IP Right Grant
- 2014-12-17 AU AU2014365899A patent/AU2014365899B2/en not_active Ceased
-
2016
- 2016-10-17 HK HK16111957.0A patent/HK1223583A1/zh unknown
-
2019
- 2019-10-18 US US16/657,147 patent/US11439807B2/en active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5645526A (en) * | 1994-09-30 | 1997-07-08 | Becton Dickinson And Company | Apparatus and method for ensuring compatibility of a reusable iontophoretic controller with an iontophoretic patch |
US20020019652A1 (en) * | 1999-07-08 | 2002-02-14 | Cyclotec Advanced Medical Technologies | Two part tens bandage |
US20040101551A1 (en) * | 2000-08-30 | 2004-05-27 | Thorsten Selzer | Transdermal therapeutic system for releasing venlafaxine |
CN1708291A (zh) * | 2001-12-05 | 2005-12-14 | Lts勒曼治疗系统股份公司 | 具有改良的长期附着舒适性的透皮治疗体系 |
Also Published As
Publication number | Publication date |
---|---|
EP2886153A1 (de) | 2015-06-24 |
EP3082942B1 (de) | 2018-02-28 |
CA2934318C (en) | 2022-02-22 |
AU2014365899B2 (en) | 2019-03-14 |
HK1223583A1 (zh) | 2017-08-04 |
RU2687090C1 (ru) | 2019-05-07 |
BR112016013278B1 (pt) | 2021-09-08 |
US20200046963A1 (en) | 2020-02-13 |
CN105873634A (zh) | 2016-08-17 |
MX2016008138A (es) | 2016-09-16 |
ES2661836T3 (es) | 2018-04-04 |
RU2016129497A (ru) | 2018-01-26 |
US20160303361A1 (en) | 2016-10-20 |
CA2934318A1 (en) | 2015-06-25 |
JP6560679B2 (ja) | 2019-08-14 |
KR20160102002A (ko) | 2016-08-26 |
BR112016013278A2 (zh) | 2017-08-08 |
JP2016540818A (ja) | 2016-12-28 |
US10485967B2 (en) | 2019-11-26 |
US11439807B2 (en) | 2022-09-13 |
WO2015090583A1 (de) | 2015-06-25 |
AU2014365899A1 (en) | 2016-07-07 |
EP3082942A1 (de) | 2016-10-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11439807B2 (en) | System for the transdermal delivery of active ingredient | |
ES2245649T3 (es) | Un sistema de entrega de farmaco dual adhesivo transdermico. | |
JP4721902B2 (ja) | 用時活性化型イオントフォレーシスデバイス | |
ES2848395T3 (es) | Parche transdérmico de fentanilo | |
US20050255150A1 (en) | Wound treatment patch for alleviating pain | |
MXPA02008828A (es) | Agentes de penetracion intradermica para administracion topica de un anestesico local. | |
ES2458627T3 (es) | Sistemas de administración transdérmica de fármaco de ketotifeno y métodos para tratar enfermedades oftálmicas | |
US20060257460A1 (en) | Multilayer drug delivery system with barrier against antagonist exposure | |
US9849270B2 (en) | Foldable adhesive composite dressing | |
US20070020321A1 (en) | Method for enhancing attenuation characteristic of absorbent materials useful with dermal and transdermal substance delivery systems | |
JP5767094B2 (ja) | 経皮的薬物投与デバイス | |
WO2014144109A1 (en) | Transdermal patch with non-water soluble adhesive and anesthetic | |
US20190015352A1 (en) | Applicators & Patches for Dermal & Transdermal Treatment Material & Drug Delivery, Methods of Making Them, & Methods of Use | |
DE102006011338A1 (de) | Pflasterverpackung | |
JP3119488B2 (ja) | 水溶性ステロイド用イオントフォレーシスデバイス | |
JPH042984Y2 (zh) | ||
CN113616626A (zh) | 具有麻醉效果的医用敷贴及其应用 | |
BR112021009956A2 (pt) | sistema terapêutico transdérmico, seu uso e seu processo de produção,kit que compreende pelo menos um sistema terapêutico transdérmico | |
AU2010202032A1 (en) | A dual adhesive transdermal drug delivery system |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |